deltatrials
Terminated PHASE2 INTERVENTIONAL 10-arm NCT05068284

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (AIM-CD)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD

Sponsor: AbbVie

Conditions Crohn's Disease
Interventions ABBV-154 Placebo
Updated 22 times since 2021 Last updated: Sep 5, 2024 Started: Jan 31, 2022 Primary completion: Jul 20, 2023 Completion: Jul 20, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic considerations

Other terminated trials from AbbVie

See all terminations from AbbVie

Other Crohn's Disease trials with similar outcome

Browse all Crohn's Disease trials

This PHASE2 trial investigates Crohn's Disease and is currently terminated or withdrawn. AbbVie leads this study, which shows 22 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Nov 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

▶ Show 17 earlier versions

  1. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  2. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  3. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  4. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  5. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  6. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  7. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  8. Oct 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  9. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  10. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  11. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  12. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  13. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  14. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  15. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  16. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  17. Nov 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Amsterdam, Netherlands , Ann Arbor, United States , Asahikawa-shi, Japan , Ashkelon, Israel , Athens, Greece , Atlanta, United States , Aurora, United States , Banská Bystrica, Slovakia , Barcelona, Spain and 134 more locations